NCT00313768 - Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

paclitaxel + carboplatin + bevacizumab

paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles

DRUG

carboplatin + paclitaxel + bevacizumab + PF-3512676

carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles

Trial Locations (29)

21231

Pfizer Investigational Site, Baltimore

27534

Pfizer Investigational Site, Goldsboro

27893

Pfizer Investigational Site, Wilson

28382

Pfizer Investigational Site, Clinton

28573

Pfizer Investigational Site, Pollocksville

31602

Pfizer Investigational Site, Valdosta

32511

Pfizer Investigational Site, Birmingham

32796

Pfizer Investigational Site, Titusville

32931

Pfizer Investigational Site, Cocoa Beach

32952

Pfizer Investigational Site, Merritt Island

32955

Pfizer Investigational Site, Rockledge

35022

Pfizer Investigational Site, Bessemer

35205

Pfizer Investigational Site, Birmingham

35209

Pfizer Investigational Site, Birmingham

35213

Pfizer Investigational Site, Birmingham

35235

Pfizer Investigational Site, Birmingham

36607

Pfizer Investigational Site, Mobile

37920

Pfizer Investigational Site, Knoxville

37934

Pfizer Investigational Site, Knoxville

60432

Pfizer Investigational Site, Joliet

60435

Pfizer Investigational Site, Joliet

78626

Pfizer Investigational Site, Georgetown

78666

Pfizer Investigational Site, San Marcos

78705

Pfizer Investigational Site, Austin

78745

Pfizer Investigational Site, Austin

78758

Pfizer Investigational Site, Austin

78759

Pfizer Investigational Site, Austin

90033

Pfizer Investigational Site, Los Angeles

92708

Pfizer Investigational Site, Fountain Valley